Improving outcome through two decades in childhood ALL in the Nordic countries: the impact of high-dose methotrexate in the reduction of CNS irradiation
- 1 December 2000
- journal article
- research article
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 14 (12), 2267-2275
- https://doi.org/10.1038/sj.leu.2401961
Abstract
In this population-based material from the five Nordic countries (Denmark, Finland, Iceland, Norway and Sweden), 2860 children below 15 years of age were diagnosed with acute lymphoblastic leukemia (ALL) from July 1981 to June 1998. The annual incidence was 3.9/100,000 children and was stable throughout the study period. The development from regional or national protocols to common Nordic treatment protocols for all risk groups was completed in 1992 through a successive intensification with multidrug chemotherapy, including pulses of methotrexate in high doses and avoidance of cranial irradiation in most children. The overall event-free survival (EFS) at 5 years has increased from 56.5 +/- 1.7% in the early 1980s to 77.6 +/- 1.4% during the 1990s. The main improvements were seen in children with non-high risk leukemia. In high-risk patients, progress has been moderate, especially in children with high WBC (> or =100 x 10(9)/l) at diagnosis. During the last time period (January 1992-June 1998), only 10% of the patients have received cranial irradiation in first remission, while 90% of the patients have received pulses of high dose methotrexate (5-8 g/m2) isolated or combined with high-dose cytosine arabinoside (total dose 12 g/m2) plus multiple intrathecal injections of methotrexate as CNS-targeted treatment, not translating into increased cumulative incidence of CNS relapse.Keywords
This publication has 16 references indexed in Scilit:
- Prognostic impact of karyotypic findings in childhood acute lymphoblastic leukaemia: a Nordic series comparing two treatment periodsBritish Journal of Haematology, 2000
- Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhoodThe Lancet, 1998
- Intensified treatment of acute childhood lymphoblastic leukaemia has improved prognosis, especially in non‐high‐risk patients: the Nordic experience of 2648 patients diagnosed between 1981 and 1996Acta Paediatrica, 1998
- Impact of Morning Versus Evening Schedule for Oral Methotrexate and 6-Mercaptopurine on Relapse Risk for Children with Acute Lymphoblastic LeukemiaJournal of Pediatric Hematology/Oncology, 1997
- Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukaemiaThe Lancet, 1994
- A Population‐Based Study of Children with Standard Risk Acute Lymphoblastic Leukemia in the Five Nordic CountriesActa Paediatrica, 1989
- A Population‐Based Study of Childhood Acute Lymphoblastic Leukemia Diagnosed from July 1981 through June 1985 in the Five Nordic CountriesActa Paediatrica, 1987
- Methotrexate infusions in poor prognosis acute lymphoblastic leukemia: II. High-dose methotrexate (HDM) in acute lymphoblastic leukemia in childhood: A pilot study from April 1981Medical and Pediatric Oncology, 1986
- Recent advances in the management of acute lymphocytic leukemiaEuropean Paediatric Haematology and Oncology, 1984
- INTERMEDIATE DOSE METHOTREXATE (IDM) IN CHILDHOOD ACUTE LYMPHOCYTIC LEUKEMIA IN NORWAYActa Paediatrica, 1981